Please assess the completion status of the following clinical trial:

Trial Title: Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DSM IV defined autism and meets cut off on Autism Diagnostic Inventory-Revised (ADI-R) and/or the Autism Diagnostic Observation Scale (ADOS)~* Age 3 through 7 years~* IQ of 50 or above~* Parental agreement to continue present dietary, behavioral or psychotropic drug treatment but not change treatment during 8 week intervention~* Willingness to have blood drawn, without the use of a sedative prescription from the study doctor~Exclusion Criteria:~* Bleeding disorder~* Cancer~* Seizure disorder~* Fragile X or other known genetic cause of autism~* Perinatal brain injury (i.e.: cerebral palsy)~* Other serious medical illnesses~* Current use of any B12 supplement

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Active (Type: EXPERIMENTAL): Active Methyl B12

Based on this trial design, predict the completion outcome and termination type (if applicable).